Caribou Biosciences and the Jackson Laboratory Enter into License Agreement for CRISPR-Cas9
Caribou and JAX entered into a license agreement for Caribou’s CRISPR-Cas9 gene editing technology.
On Oct. 25, 2016 Caribou Biosciences and the Jackson Laboratory (JAX) entered into a license agreement to give JAX non-exclusive worldwide rights to Caribou’s CRISPR-Cas9 intellectual property. JAX will use the technology to create genetically engineered mice for research, Caribou said in a press announcement.
Caribou's CRISPR-Cas9 technology targets and cuts DNA to produce precise and controllable changes to the genome. JAX’s will use the gene editing technology to create mouse models that better recapitulate human diseases, enabling researchers to find treatments more quickly. The license from Caribou includes CRISPR-Cas9 technology and intellectual property owned by Caribou as well as foundational CRISPR-Cas9 intellectual property exclusively licensed to Caribou by the Regents of the University of California and the University of Vienna.
"JAX is excited to reach this CRISPR-Cas9 IP agreement with Caribou," said Edison Liu, MD, president and CEO of JAX. "CRISPR technology has transformed genetic engineering in nearly all biological systems. This license allows us to deliver custom-built mouse models, creating the next generation of predictive models for the new era of personalized medicine."
Source: Caribou
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
